Gynecologic Oncology | Specialty

Neoadjuvant Chemotherapy for Ovarian Cancer

November 26th 2014

Timing of Oophorectomy in Ovarian Cancer

November 26th 2014

Prophylactic Oophorectomy for Reducing Ovarian Cancer Risk

November 26th 2014

Universal Screening for BRCA1 and BRCA2 Mutations

November 26th 2014

Cediranib Combined With Chemotherapy Improves PFS in Advanced Cervical Cancer

September 28th 2014

Cediranib improved response rate and median PFS when added to conventional chemotherapy in a phase II study of patients with relapsed or metastatic cervical cancer.

DHEA Therapy Offers Relief From Vaginal Symptoms in Cancer Survivors

August 21st 2014

A randomized multicenter trial examining the efficacy of adding dehydroepiandosterone (DHEA) to a vaginal bioadhesive moisturizer in postmenopausal survivors of breast or gynecologic cancer has found that daily rather than as-needed use of such a moisturizer significantly relieves symptoms of vaginal atrophy in these women.

FDA Approves Bevacizumab for Advanced Cervical Cancer

August 14th 2014

The FDA has approved bevacizumab in combination with paclitaxel and cisplatin or paclitaxel and topotecan as a treatment for patients with persistent, recurrent, or metastatic cervical cancer.

Immunotherapy Branches Out

July 18th 2014

Immunotherapy agents are delivering impressive results in a broad range of tumor types, reinforcing the excitement in research and investment circles for anticancer strategies that actively harness the immune system

FDA Grants Priority Review to Bevacizumab in Advanced Cervical Cancer

July 15th 2014

The FDA has assigned a priority review designation to bevacizumab (Avastin) plus chemotherapy as a treatment for patients with persistent, recurrent, or metastatic cervical cancer.

Dr. Monk on Bevacizumab in Recurrent Cervical Cancer

July 14th 2014

Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses the utility of bevacizumab in recurrent cervical cancer.

HPV-Targeting Immunotherapy Shows Early Promise in Cervical Cancer

June 2nd 2014

Two patients with metastatic cervical cancer achieved durable complete responses that have so far lasted from 15 to 22 months through an adoptive T-cell therapy (ACT) targeting the human papillomavirus (HPV) in a study that researchers say supports the concept that the experimental immunotherapy approach may be beneficial in a variety of tumor types.

Study Suggests More Than Two-Thirds of Healthy Americans Are Infected with Human Papilloma Viruses

May 28th 2014

Only a Few of More Than 109 Detected Strains Known to Cause Cancer

HPV Test With Genotyping Tops Cervical Cancer Screening Strategies

May 27th 2014

Cervical cancer screening based on identification of human papillomavirus (HPV) strains outperformed primary liquid cytology for detection of high-grade cervical intraepithelial neoplasia (CIN), data from a large cohort study showed.

For Premenopausal Women With ER-Positive Disease, Obesity Is a Major Risk Factor in Breast Cancer Mortality

May 14th 2014

Obesity significantly increases the risk of dying of breast cancer in premenopausal women with ER-positive early disease.

FDA Approves First HPV Test for Primary Cervical Cancer Screening

April 24th 2014

The FDA has approved the cobas HPV Test as a first-line screening tool for cervical cancer in women 25 and older, making it the first-ever approval for a diagnostic alternative to Pap smear.

Angiogenesis-Targeting Agents Poised to Become a Mainstay of Gynecologic Cancer Treatment

January 3rd 2014

Antiangiogenic agents hold promise in gynecologic cancers, as evidenced by their single-agent activity in malignancies including ovarian cancer, recurrent endometrial cancer, and cervical cancer.

Dr. Monk on Bevacizumab in Cervical Cancer

December 31st 2013

Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses the role of bevacizumab in the treatment of metastatic cervical cancer.

No Survival Benefit Found in LRT for Women Presenting With Metastatic Breast Cancer

December 13th 2013

In women with metastatic breast cancer that responds to frontline chemotherapy, locoregional treatment (LRT) of the primary tumor and axillary nodes does not produce an increase in overall survival (OS),

Dr. Monk Discusses the TRINOVA-1 Trial

November 20th 2013

Bradley J. Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses the TRINOVA-1 trial.

Immunotherapy Examined as Treatment Option in Locally Advanced Cervical Cancer

November 5th 2013

The notion of commandeering the immune system to treat cancer actually dates back more than a century with intratumoral bacterial injections to try and elicit tumor regression.